title: Hemodynamic effects of sildenafil in patients with stable ischemic heart disease.
abstract: BACKGROUND
  Recently the new specific phosphodiesterase-5 inhibitor sildenafil was introduced into therapy for erectile dysfunction. The hemodynamic effects of sildenafil may be potentially hazardous for patients with cardiac disease. Sildenafil has been reported to augment the hypotensive effects of nitrates. There is sparse information regarding the systemic and pulmonary hemodynamic effects of a single oral dose of sildenafil in patients with stable angina.
  
  
  METHODS
  Male patients referred for coronary angiography with diagnosis of chronic stable angina were enrolled in this study to assess the acute hemodynamic effects of sildenafil. Patients receiving long-acting or sublingual nitrates for the last 6 h before the study were excluded. Hemodynamic measurement were taken during right and left heart catheterization in the basal state and 60 min after 50 mg of oral sildenafil.
  
  
  RESULTS
  Twelve patients (age 53+/-7 years) were studied. All had stable angina CCS class II or III. Four had previous myocardial infarction. By coronary angiography, seven patients had at least one coronary artery with >70% stenosis, four had at least one with 50-70% stenosis, and one had only intimal irregularities. There were no significant effects of sildenafil on systemic or pulmonary arterial pressure, left ventricle end diastolic pressure, cardiac output, and systemic or pulmonary vascular resistance (P>0.05 for all). No adverse events were observed.
  
  
  CONCLUSIONS
  A single oral dose of sildenafil had no significant hemodynamic effect in supine patients with stable angina. Isolated administration of sildenafil does not appear to be associated to adverse cardiovascular effects.
authors.affiliation: Unidade de Hemodinâmica, Serviço de Cardiologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. wmanfroi@terra.com.br
authors.forename: Waldomiro C
authors.initials: WC
authors.lastname: Manfroi
authors.forename: Paulo R A
authors.initials: PR
authors.lastname: Caramori
authors.forename: Alcides J
authors.initials: AJ
authors.lastname: Zago
authors.forename: Raquel
authors.initials: R
authors.lastname: Melchior
authors.forename: Vanessa
authors.initials: V
authors.lastname: Zen
authors.forename: Melissa
authors.initials: M
authors.lastname: Accordi
authors.forename: Danielle
authors.initials: D
authors.lastname: Gutierres
authors.forename: Clarissa
authors.initials: C
authors.lastname: Noer
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000000981:diagnostic imaging / Q000503:physiopathology*; D017023:Coronary Angiography; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate